Business
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platformRUTHERFORD, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has submitted its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administratio
About this update from Glucotrack, Inc.
[{"type":"image","alt":"Glucotrack, Inc.","displaySize":"","headline":null,"caption":"Glucotrack, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/55d126c2f85c074ae4df3a352637b3fb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wXqQ4CyH8jC1otLKDaakMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkw/https://media.zenfs.com/en/globenewswire.com/55d126c2f85c074ae4df3a352637b3fb","width":300,"height":64}},"lazy":false},{"type":"text","content":"Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform","length":117,"tagName":"p"},{"type":"text","content":"RUTHERFORD, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has submitted its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a US clinical study for its fully implantable continuous blood glucose monitoring (CBGM) technology.","length":503,"tagName":"p"},{"type":"text","content":"The IDE submission represents an important step for Glucotrack and reflects the Company’s progress to date in its preclinical development and technical foundation of the technology. With this submission, Glucotrack moves closer to advancing its implantable monitoring system toward clinical evaluation in the United States, with the goal of offering people with diabetes a new option for continuous glucose monitoring designed to provide long-term, real-time, blood-based accuracy without an on-body wearable. The Company plans to proceed with its U.S. clinical study following FDA review and approval.","length":602,"tagName":"p"},{"type":"text","content":"“Submission of our IDE represents meaningful progress in the development of our CBGM technology and underscores our commitment to helping people with diabetes live more fully,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “Our fully implantable solution is designed to be comfortable and discreet so that people can focus on their daily lives – allowing them to work, exercise, sleep, and socialize without the disruption of frequent sen...